Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Long-Term Investments (2021 - 2025)

Historic Long-Term Investments for Pharmaceuticals (CASI) over the last 5 years, with Q2 2025 value amounting to $1.7 million.

  • Pharmaceuticals' Long-Term Investments fell 9990.32% to $1.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.7 million, marking a year-over-year decrease of 9990.32%. This contributed to the annual value of $1.9 million for FY2024, which is 9988.65% down from last year.
  • According to the latest figures from Q2 2025, Pharmaceuticals' Long-Term Investments is $1.7 million, which was down 9990.32% from $1.9 billion recorded in Q1 2025.
  • In the past 5 years, Pharmaceuticals' Long-Term Investments ranged from a high of $3.6 billion in Q2 2023 and a low of $1.7 million during Q1 2024
  • For the 5-year period, Pharmaceuticals' Long-Term Investments averaged around $1.0 billion, with its median value being $40.1 million (2021).
  • Within the past 5 years, the most significant YoY rise in Pharmaceuticals' Long-Term Investments was 11349050.45% (2025), while the steepest drop was 9990.32% (2025).
  • Quarter analysis of 5 years shows Pharmaceuticals' Long-Term Investments stood at $40.1 million in 2021, then tumbled by 89.04% to $4.4 million in 2022, then skyrocketed by 38235.61% to $1.7 billion in 2023, then crashed by 99.89% to $1.9 million in 2024, then fell by 10.3% to $1.7 million in 2025.
  • Its Long-Term Investments was $1.7 million in Q2 2025, compared to $1.9 billion in Q1 2025 and $1.9 million in Q4 2024.